NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has entered into a collaboration with investigators at City of Hope, a leading biomedical research and treatment center, in the development of a vaccine for the treatment of certain forms of leukemia and lymphoma based upon the Company’s proprietary Lm vaccine technology platform.
